We found that patients with combined high ERβ + negative ERα expression had significantly lower IRSs of tumor-promoting proteins, such as CysLT1R, COX-2 and nuclear β-catenin, and higher IRSs of anti-tumorigenic proteins such as CysLT2R, membrane β-catenin, 15-PGDH and PGD2 synthase, compared to patients with combined low ERβ + positive ERα expression. This evidence concerns the gene PTGS2 and neoplasm.